Omeprazole magnesium

Base Information

• Chemical Name: Omeprazole magnesium
• CAS No.: 161796-78-7
• Molecular Formula: C17H20N3NaO3S
• Molecular Weight: 369.41
• Hs Code.: 2933990090
• European Community (EC) Number: 620-470-6,627-029-7,630-398-7,669-839-3
• NCI Thesaurus Code: C29032,C65539,C66256
• RXCUI: 236486,283562,1294569
• Mol file: 161796-78-7.mol

Synonyms:Esomeprazole;Esomeprazole Magnesium;Esomeprazole Potassium;Esomeprazole Sodium;Esomeprazole Strontium;Esomeprazole Strontium Anhydrous;Nexium;Strontium, Esomeprazole

Chemical Property of Omeprazole magnesium

Chemical Property:

• Melting Point: 156 °C (approx)
• Boiling Point: 618.9 °C at 760 mmHg
• Flash Point: 328.1 °C
• PSA: 85.45000
• LogP: 3.55120
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility.: DMSO (Slightly, Sonicated), Methanol (Slightly), Water (Slightly)
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 10
• Exact Mass: 712.1988169
• Heavy Atom Count: 49
• Complexity: 993

Purity/Quality:

99.5% ^*data from raw suppliers

(S)-OmeprazoleSodiumSalt ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2]
• Recent ClinicalTrials: High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
• Recent EU Clinical Trials: 'A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age'
• Indications: For the treatment of Gastroesophageal reflux disease (GERD)-erosive reflux esophagitis. Used for long-term maintenance therapy for cured esophagitis patients to prevent recurrence. Symptomatic control of gastroesophageal reflux disease (GERD). Heartburn and combined with other appropriate antimicrobial therapy for totally eradication of Helicobacter pylori-induced gastric and duodenal ulcers.
• Drug Interactions: Esomeprazole sodium can reduce the absorption of ketoconazole and itraconazole. When combined with the product, we should reduce the dosages of drugs metabolized by the enzyme CYP2C19 such as diazepam, citalopram, imipramine, clomipramine and phenytoin. When combined with the product or stop using this product, we should also monitor the plasma concentrations of phenytoin. No interaction between the product and the amoxicillin, quinidine or warfarin was observed. No need for dose adjustment when combined with clarithromycin. There is not too much clinical information of excess taking drug. But a single dose of 80 mg of this product has no adverse reactions. This product has no special antidote.
• Uses: Treatment of peptic ulcer, gastroesophageal reflux disease and other acid-related diseases. Esomeprazole sodium is a commonly used anti-ulcer drug. It was successfully developed by AstraZeneca for the first time. It is a proton pump inhibitor. The drug of choice for related diseases. (S)-Omeprazole is the (S)-enantiomer of Omeprazole (O635000) a gastric proton-pump inhibitor. (S)-Omeprazole is more potent that its (R)-enantiomer and is used in the treatment of gastroesophageal ref lux disease as well as gastrointestinal ulcers associated with Crohn's disease.